Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 7/20 | 0.96 |
| ▸ | AVPR1B | P47901 | 5/20 | 0.96 |
| ▸ | AVPR2 | P30518 | 4/20 | 0.96 |
| ▸ | OXTR | P30559 | 4/20 | 0.96 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.84 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.68 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.68 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19733909 | 1.00 | AVPR1A (0.96) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL19712236 | 0.98 | AVPR1A (1.00) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL19705283 | 0.98 | AVPR1A (0.92) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL18937546 | 0.98 | AVPR1A (1.00) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL17874853 | 0.98 | AVPR1A (1.00) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL29688276 | 0.98 | AVPR1A (1.00) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL29530914 | 0.96 | AVPR1A (0.97) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL18476287 | 0.96 | AVPR1A (0.96) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL23879427 | 0.96 | AVPR1A (0.96) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL1172390 | 0.95 | AVPR1A (0.95) | AVPR1AAVPR1BAVPR2OXTRPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220133838-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133838-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | AVPR2, AVPR1B, AVPR1A | AVPR1A 3/4885AVPR1B 2/4885AVPR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.